Initial characteristics of the patients according to the treatment group
. | ACVBP n = 323 (%) . | CHOP n = 312 (%) . | P . |
|---|---|---|---|
| Median age, y | 65 | 65 | |
| Sex | 0.9 | ||
| Male | 182 (56) | 177 (57) | |
| Female | 141 (44) | 135 (43) | |
| Histology | 0.8 | ||
| Diffuse large B cell | 257 (80) | 244 (78) | |
| Burkitt | 5 (1) | 6 (2) | |
| Lymphoblastic | 3 (1) | 3 (1) | |
| Peripheral T-cell NOS | 29 (9) | 28 (9) | |
| Angio-immunoblastic T cell | 8 (2) | 11 (4) | |
| Anaplastic large-cell T/NK | 12 (4) | 10 (3) | |
| Aggressive unclassifiable | 9 (3) | 10 (3) | |
| Immunophenotype* | 0.5 | ||
| B | 263 (85) | 253 (84) | |
| T | 47 (15) | 49 (16) | |
| B symptoms* | 0.2 | ||
| Absent | 163 (51) | 142 (46) | |
| Present | 155 (49) | 168 (54) | |
| Performance status (ECOG) | 1 | ||
| 0-1 | 220 (68) | 212 (68) | |
| Greater than 1 | 103 (32) | 100 (32) | |
| Ann Arbor stage | 0.6 | ||
| I-II | 56 (17) | 59 (19) | |
| III-IV | 267 (83) | 253 (81) | |
| Number of extranodal sites* | 0.8 | ||
| 0-1 | 163 (51) | 156 (50) | |
| More than 1 | 155 (49) | 156 (50) | |
| Sites of extranodal involvement* | |||
| Bone marrow | 78 (24) | 96 (31) | 0.08 |
| Liver | 34 (10) | 44 (14) | 0.2 |
| Spleen | 78 (24) | 75 (24) | 0.9 |
| Skin | 24 (7) | 14 (4) | 0.1 |
| Lungs | 27 (8) | 39 (12) | 0.09 |
| Head and Neck | 34 (11) | 28 (9) | 0.5 |
| Epidural involvement | 9 (3) | 10 (3) | 0.8 |
| Serum LDH level | 0.1 | ||
| N or less | 92 (28) | 71 (23) | |
| Greater than N | 231 (72) | 241 (77) | |
| Serum albumin level* | 0.4 | ||
| Less than 35 g/L | 169 (56) | 151 (52) | |
| 35 g/L or greater | 133 (44) | 138 (48) | |
| Number of age-adjusted IPI factors | 0.6 | ||
| 1 | 113 (35) | 105 (34) | |
| 2 | 142 (44) | 130 (42) | |
| 3 | 68 (21) | 77 (24) |
. | ACVBP n = 323 (%) . | CHOP n = 312 (%) . | P . |
|---|---|---|---|
| Median age, y | 65 | 65 | |
| Sex | 0.9 | ||
| Male | 182 (56) | 177 (57) | |
| Female | 141 (44) | 135 (43) | |
| Histology | 0.8 | ||
| Diffuse large B cell | 257 (80) | 244 (78) | |
| Burkitt | 5 (1) | 6 (2) | |
| Lymphoblastic | 3 (1) | 3 (1) | |
| Peripheral T-cell NOS | 29 (9) | 28 (9) | |
| Angio-immunoblastic T cell | 8 (2) | 11 (4) | |
| Anaplastic large-cell T/NK | 12 (4) | 10 (3) | |
| Aggressive unclassifiable | 9 (3) | 10 (3) | |
| Immunophenotype* | 0.5 | ||
| B | 263 (85) | 253 (84) | |
| T | 47 (15) | 49 (16) | |
| B symptoms* | 0.2 | ||
| Absent | 163 (51) | 142 (46) | |
| Present | 155 (49) | 168 (54) | |
| Performance status (ECOG) | 1 | ||
| 0-1 | 220 (68) | 212 (68) | |
| Greater than 1 | 103 (32) | 100 (32) | |
| Ann Arbor stage | 0.6 | ||
| I-II | 56 (17) | 59 (19) | |
| III-IV | 267 (83) | 253 (81) | |
| Number of extranodal sites* | 0.8 | ||
| 0-1 | 163 (51) | 156 (50) | |
| More than 1 | 155 (49) | 156 (50) | |
| Sites of extranodal involvement* | |||
| Bone marrow | 78 (24) | 96 (31) | 0.08 |
| Liver | 34 (10) | 44 (14) | 0.2 |
| Spleen | 78 (24) | 75 (24) | 0.9 |
| Skin | 24 (7) | 14 (4) | 0.1 |
| Lungs | 27 (8) | 39 (12) | 0.09 |
| Head and Neck | 34 (11) | 28 (9) | 0.5 |
| Epidural involvement | 9 (3) | 10 (3) | 0.8 |
| Serum LDH level | 0.1 | ||
| N or less | 92 (28) | 71 (23) | |
| Greater than N | 231 (72) | 241 (77) | |
| Serum albumin level* | 0.4 | ||
| Less than 35 g/L | 169 (56) | 151 (52) | |
| 35 g/L or greater | 133 (44) | 138 (48) | |
| Number of age-adjusted IPI factors | 0.6 | ||
| 1 | 113 (35) | 105 (34) | |
| 2 | 142 (44) | 130 (42) | |
| 3 | 68 (21) | 77 (24) |
NOS indicates not otherwise specified; NK, natural killer; N, normal value; and IPI, international prognostic index for aggressive lymphoma.13
Data were unavailable for some patients.